The latest price target for Kestra Medical Techs (NASDAQ:KMTS) was reported by Goldman Sachs on December 15, 2025. The analyst firm set a price target for $25.00 expecting KMTS to rise to within 12 months (a possible 29.80% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Kestra Medical Techs (NASDAQ:KMTS) was provided by Goldman Sachs, and Kestra Medical Techs maintained their neutral rating.

There is no last upgrade for Kestra Medical Techs

There is no last downgrade for Kestra Medical Techs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kestra Medical Techs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kestra Medical Techs was filed on December 15, 2025 so you should expect the next rating to be made available sometime around December 15, 2026.

While ratings are subjective and will change, the latest Kestra Medical Techs (KMTS) rating was a maintained with a price target of $22.00 to $25.00. The current price Kestra Medical Techs (KMTS) is trading at is $19.26, which is out of the analyst’s predicted range.